Literature DB >> 1915845

Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues.

P Pradelles1, Y Frobert, C Créminon, H Ivonine, E Frindel.   

Abstract

A competitive enzyme immunoassay using acetylcholinesterase as tracer for thymosin beta 4, has been developed. Using this assay and a previously described EIA for AcSDKP, a negative regulator of pluripotent haematopoietic stem cell proliferation, the levels of these two peptides were determined in mouse tissue extracts. The combination of EIAs with different HPLC procedures validated these methods and clearly demonstrated the ubiquity of these peptides in mouse tissues. Similar results are reported for rabbit thymus which suggest different hypotheses for AcSDKP biosynthesis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1915845     DOI： 10.1016/0014-5793(91)81062-d

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  22 in total

1.  Distribution and biological activity ofβ-thymosins.

Authors:  M Mihelić; W Voelter
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

2.  Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.

Authors:  Cesar A Romero; Nitin Kumar; Pablo Nakagawa; Morel E Worou; Tang-Dong Liao; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-07

3.  AcSDKP: a new potential marker of malignancy of the thyroid gland.

Authors:  Michal Kusinski; Joanna Wdzieczak-Bakala; Jian-Miao Liu; Jerome Bignon; Krzysztof Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2006-01-18       Impact factor: 3.445

4.  Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.

Authors:  N E Rhaleb; H Peng; P Harding; M Tayeh; M C LaPointe; O A Carretero
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

5.  Angiotensin-converting enzyme inhibitors: a new mechanism of action.

Authors:  Hongmei Peng; Oscar A Carretero; Nikola Vuljaj; Tang-Dong Liao; Apurva Motivala; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Circulation       Date:  2005-10-10       Impact factor: 29.690

6.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

7.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

8.  Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.

Authors:  Lei Zhang; Lei-Ming Xu; Yuan-Wen Chen; Qian-Wen Ni; Min Zhou; Chun-Ying Qu; Yi Zhang
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

9.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

10.  N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts.

Authors:  Hongmei Peng; Oscar A Carretero; Edward L Peterson; Xiao-Ping Yang; Kastuv Santra; Nour-Eddine Rhaleb
Journal:  Pflugers Arch       Date:  2012-09-12       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.